Latest Omeros Corporation Stories
-- Phase 2 Program Expected to Initiate this Quarter -- SEATTLE, Feb. 3, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data following completion of dosing in a Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. OMS721, administered either by subcutaneous injection or intravenous infusion, was...
- Data expand potential indications both within schizophrenia and to other neuropsychiatric disorders - SEATTLE, Jan. 29, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients...
- Remarkable; prodigious.
- Audacious; gutsy.
- Completely; extremely.
- Audaciously; boldly.
- Impressively great in size; enormous; extraordinary.